β-Blockers and reverse remodeling: What are the implications?
Authors:
- Gary S. FrancisGFGary S. Francis
- W.H.Wilson TangWTW.H.Wilson Tang
- 1 February 2003
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 145 (2) , 200-202
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Marked improvement in left ventricular ejection fraction during long-term β-blockade in patients with chronic heart failure: Clinical correlates and prognostic significanceAmerican Heart Journal, 2003
- Surrogate end points in heart failureJACC, 2002
- Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failureJACC, 2002
- Reverse remodeling following long-term carvedilol therapy is associated with improvement in survival: the stanford carvedilol echocardiographic registryJACC, 2002
- Surrogate End Points in Heart FailureAnnals of Pharmacotherapy, 2002
- Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodelingJACC, 2000
- Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathyThe American Journal of Cardiology, 1999
- Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failureThe American Journal of Cardiology, 1999
- Reverse remodeling in heart failure with intensification of vasodilator therapyClinical Cardiology, 1997
- Marked spontaneous improvement in ejection fraction in patients with congestive heart failureThe American Journal of Medicine, 1990